Neurocrine Biosciences (NBIX) Interest & Investment Income (2010 - 2026)

Neurocrine Biosciences has reported Interest & Investment Income for 17 years, with the latest figure at $28.1 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income rose 29.49% year-over-year to $28.1 million; the trailing twelve-month figure through Mar 2026 stood at $96.7 million (up 6.97% YoY), and the FY2025 full-year result was $90.3 million, down 0.77% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $28.1 million, up from $25.8 million in the prior quarter.
• The five-year high for Interest & Investment Income was $28.1 million in Q1 2026, with the low at $200000.0 in Q3 2022.
• Historically, Interest & Investment Income has averaged $15.7 million across 5 years, with a median of $20.6 million in 2025.
• Annual changes were most pronounced in 2022 — Interest & Investment Income sank 75.0% — and 2023, when it surged 7150.0%.
• Neurocrine Biosciences' Interest & Investment Income stood at $1.3 million in 2022, then surged by 1353.85% to $18.9 million in 2023, then advanced by 19.05% to $22.5 million in 2024, then advanced by 14.67% to $25.8 million in 2025, then gained by 8.91% to $28.1 million in 2026.
• The last three Interest & Investment Income figures came in at $28.1 million (Q1 2026), $25.8 million (Q4 2025), and $22.2 million (Q3 2025), per Business Quant data.